Dosimetric Considerations for 177Lu-DOTATATE Therapy in a Patient With Chronic Renal Failure Under Hemodialysis.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
This case report explores the use of 177Lu-DOTATATE in a hemodialysis patient. For the first time, this study assesses the average dose received by the bone marrow, the primary organ at risk, using an original double estimation method through independently acquired imaging and biological samples counting data. Despite elevated doses, the absorbed doses to the bone marrow (0.662-0.740 Gy) were within safe limits. Radiation protection measurements for staff were also compliant. This work supports that effective early dialysis and systematic personalized dosimetry are crucial for hemodialysis patients undergoing 177Lu-PRRT due to their variability (residual excretion, treatment history, etc).
Identifiants
pubmed: 38739496
doi: 10.1097/RLU.0000000000005262
pii: 00003072-990000000-01100
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared. Conflicts of interest and sources of funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Références
Adam D, Grudzinski J, Bradshaw T, et al. Clinical Lu-177-DOTATATE voxel-level Monte Carlo dosimetry for a patient with reduced kidney function undergoing hemodialysis. J Nucl Med. 2022;63(supplement 2):2251.
Sandström M, Garske-Román U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-Octreotate treatment. J Nucl Med. 2013;54:33–41.
Svensson J, Rydén T, Hagmarker L, et al. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016;3:21.
Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–1146.
Sjögreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778–1809.
Olmstead C, Cruz K, Stodilka R, et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nucl Med Commun. 2015;36:129–134.
Levart D, Kalogianni E, Corcoran B, et al. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6:7.
Kalogianni E, Ruiz DL, Corcoran BJ, et al. 177 Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis—dosimetric considerations. BJRcase Rep. 2015;1:20150177.
Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka experience. Theranostics. 2012;2:437–447.